Interest in JAK/STAT pathway inhibition downstream of disease-associated cytokines such as IFN-γ as a potential treatment for vitiligo has grown in recent years and resulted in several clinical trials [24–28] and the approval of ruxolitinib cream, a topical JAK1/2 inhibitor for the treatment of NSV [28, 29]. This evidence concerns the gene IFNG and vitiligo.